Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis

Abstract

BackgroundThe systemic immune-inflammation index (SII) has been recognized as the indicator that reflects the status of immune responses. The SII is related to the prognostic outcome of many malignancies, whereas its role in gliomas is controversial. For patients with glioma, we, therefore, conducted a meta-analysis to determine if the SII has a prognostic value.MethodsStudies relevant to this topic were searched from 16 October 2022 in several databases. In patients with glioma, the relation of the SII level with the patient prognosis was analyzed based on hazard ratios (HRs) as well as corresponding 95% confidence intervals (CIs). Moreover, subgroup analysis was conducted to examine a possible heterogeneity source.ResultsThere were eight articles involving 1,426 cases enrolled in the present meta-analysis. The increased SII level predicted the dismal overall survival (OS) (HR = 1.81, 95% CI = 1.55–2.12, p < 0.001) of glioma cases. Furthermore, an increased SII level also predicted the prognosis of progression-free survival (PFS) (HR = 1.87, 95% CI = 1.44–2.43, p < 0.001) in gliomas. An increased SII was significantly associated with a Ki-67 index of ≥30% (OR = 1.72, 95% CI = 1.10–2.69, p = 0.017). However, a high SII was not correlated with gender (OR = 1.05, 95% CI = 0.78–1.41, p = 0.734), KPS score (OR = 0.64, 95% CI = 0.17–2.37, p = 0.505), or symptom duration (OR 1.22, 95% CI 0.37–4.06, p = 0.745).ConclusionThere was a significant relation between an increased SII level with poor OS and the PFS of glioma cases. Moreover, patients with glioma with a high SII value have a positive relationship with a Ki-67 of ≥30%.

Prognostic and clinicopathological impacts of systemic immune-inflammation index on patients with diffuse large B-cell lymphoma: a meta-analysis

“…In recent years, numerous meta-analyses have demonstrated that the SII is of great significance TherapeuTic advances in hematology in predicting the prognosis of various solid tumors. [31][32][33][34][35] Zhang et al 31 demonstrated that a higher SII indicated poor OS and PFS in glioma cases in their meta-analysis that included eight articles. As revealed by Zeng et al, 35 a high SII remarkably predicted poor OS and PFS in patients with NPC in a meta-analysis comprising 2169 subjects.…”

“…In recent years, numerous meta-analyses have demonstrated that the SII is of great significance in predicting the prognosis of various solid tumors. 31–35 Zhang et al. 31 demonstrated that a higher SII indicated poor OS and PFS in glioma cases in their meta-analysis that included eight articles.…”

“…31–35 Zhang et al. 31 demonstrated that a higher SII indicated poor OS and PFS in glioma cases in their meta-analysis that included eight articles. As revealed by Zeng et al ., 35 a high SII remarkably predicted poor OS and PFS in patients with NPC in a meta-analysis comprising 2169 subjects.…”

Systemic and local immunosuppression in glioblastoma and its prognostic significance

“…The prognostic/predictive power of NLR may be further improved by combining NLR assessment with other biomarkers. According to recent meta-analyses and systematic reviews, absolute/total lymphocyte count (ALC/TLC, especially post-treatment) ( 321 ), platelet-to-lymphocyte ratio (PLR) ( 133 , 322 ), lymphocyte-to-monocyte ratio (LMR) ( 323 ), systemic immune-inflammation index (SII), calculated by platelet count×neutrophil count/lymphocyte count ( 129 , 324 ), and systemic immune response index (SIRI), calculated by neutrophil count×monocyte/lymphocyte count ( 325 – 327 ) are the emerging prognostic factors in glioblastoma/glioma. In a retrospective study, Yang et al.…”

Prognostic value of the systemic immune-inflammation index in patients with acute respiratory distress syndrome: A retrospective study

“…Inflammation is a pivotal factor in the advancement of critical illnesses and is frequently linked with ARDS, consequently elevating the mortality risk [ 17 , 18 ]. ystemic immune-inflammatory index (SII) was initially characterized as a potential biomarker or the assessment of tumor proliferation and cardiovascular disease pathogenesis [ [19] , [20] , [21] ].SII was calculated as platelets count x neutrophils count/lymphocytes count, and it is now considered to reflect inflammation status better [ 22 , 23 ].The SII has been effectively used to evaluate prognosis in patients suffering from various conditions, including stroke [ 24 ] and cancer [ 25 ]. However, the correlation between SII and the prognosis of patients with ARDS is still not well-established and warrants further exploration.…”